Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
David Zanoni is ranked in the top 1% of blogging analysts on Tipranks.com for performance and accuracy. He focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. David is a graduate of Rutgers University with a B.S. in Management. He is an independent long term investor of quality stocks and uses options for strategy. David believes in the power of innovation, capitalism, and the characteristics of the American spirit: intellect, fortitude, and adaptability to lead our country and the world to growing prosperity. His wants to help make people money by investing in high-quality growth stocks.
I am currently a student working on obtaining a Master's degree in Biomedical Sciences, and I have completed a Bachelor's in Biotechnology.
While my background in biotechnology gives me a great perspective into high growth companies, I prefer to focus on equities that are undervalued no matter what sector they fall under. I focus on fundamentals such as Price/Free-Cash-Flow and Price/Book to determine the ideal value of the company and I research management and their prior experience to determine whether to discount or add a premium to the ideal value. I do not use technical data to determine what makes a good investment. Rather, I use it to determine when is the best time to open or close a position in a company that I have determined to be undervalued or overvalued.
I trained in surgery before switching to strategy consulting. After several years of advising executives in the pharmaceutical and biotech industries I decided to take some time off to apply some of what I had learned about healthcare (both at the bedside and in the boardroom) to investing.